Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Ray-Coquard

Showing results (401-410 of 509) with videos related to

Pageof 51
Sort By:
The Lancet. Oncology|August 10, 2024
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trialJean-Yves Blay, Quentin Devin, Florence Duffaud, et al.
Cancers|February 9, 2021
Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study ProtocolDide den Hollander, Marco Fiore, Javier Martin-Broto, et al.
Bulletin Du Cancer|March 17, 2018
[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]Marianne Lorcet, Alain Lortholary, Jean Emmanuel Kurtz, et al.
Oncogene|November 9, 2023
Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trialCeline Callens, Manuel Rodrigues, Adrien Briaux, et al.
European Journal of Cancer (Oxford, England : 1990)|July 28, 2019
Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programmeRomain Varnier, Olivia Le Saux, Sylvie Chabaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2014
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumorsEric Angevin, Josep Tabernero, Elena Elez, et al.
Bulletin Du Cancer|September 24, 2004
[Clinical practice guidelines: Standards, Options and Recommendations for first line medical treatment of patients with ovarian neoplasms (summary report)]Catherine Lhommé, Isabelle Ray-Coquard, Jean-Pierre Guastalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA TrialBenoit You, Patrick Robelin, Michel Tod, et al.
BMC Cancer|February 14, 2020
Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)Anna Patrikidou, Loic Chaigneau, Nicolas Isambert, et al.
British Journal of Cancer|October 13, 2017
Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcomaCarmela Dantas-Barbosa, Tom Lesluyes, François Le Loarer, et al.
Pageof 51

Showing results (401-410 of 509) with videos related to

Sort By:
Pageof 51
The Lancet. Oncology|August 10, 2024
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trialJean-Yves Blay, Quentin Devin, Florence Duffaud, et al.
Cancers|February 9, 2021
Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study ProtocolDide den Hollander, Marco Fiore, Javier Martin-Broto, et al.
Bulletin Du Cancer|March 17, 2018
[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]Marianne Lorcet, Alain Lortholary, Jean Emmanuel Kurtz, et al.
Oncogene|November 9, 2023
Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trialCeline Callens, Manuel Rodrigues, Adrien Briaux, et al.
European Journal of Cancer (Oxford, England : 1990)|July 28, 2019
Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programmeRomain Varnier, Olivia Le Saux, Sylvie Chabaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2014
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumorsEric Angevin, Josep Tabernero, Elena Elez, et al.
Bulletin Du Cancer|September 24, 2004
[Clinical practice guidelines: Standards, Options and Recommendations for first line medical treatment of patients with ovarian neoplasms (summary report)]Catherine Lhommé, Isabelle Ray-Coquard, Jean-Pierre Guastalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA TrialBenoit You, Patrick Robelin, Michel Tod, et al.
BMC Cancer|February 14, 2020
Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)Anna Patrikidou, Loic Chaigneau, Nicolas Isambert, et al.
British Journal of Cancer|October 13, 2017
Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcomaCarmela Dantas-Barbosa, Tom Lesluyes, François Le Loarer, et al.
Pageof 51